secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2021-08-30T23:59:59+00:00
Accession:  0001193125-21-260859
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ziopharm appoints Kevin S. Boyle as CEO effective Aug 30, 2021; Heidi Hagen returns to Board
--------------------------------------------------------------------------------

- Kevin S. Boyle named CEO and director; base salary $600K, target bonus 60%, sign-on bonus $50K.
- Equity awards: option for 2,625,000 shares and 875,000 RSUs, each vesting over 4 years.
- Heidi Hagen steps down as interim CEO, remains on Board (since June 2019).
- Raffaele Baffa appointed Head of R&D in addition to CMO; Adam Levy named EVP Corp Dev & IR.
- Boyle most recently CEO of Kuur Therapeutics, led $185M acquisition by Athenex in May 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/0001193125-21-260859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/d11000d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-260859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer